
Sign up to save your podcasts
Or


Kimon Hatza, Esq. of GrowthCounsel interviews Nikej N. Shah, M.D., CEO of Nirsum Laboratories about issues in Long-term opioid therapy: Unmet needs, Risks and Solutions with a new drug in Phase I testing with the FDA. Present drugs in use today are Bupremorphine, Methadone and Maltrexone.
The post Money Matters TV 24-42 Shah appeared first on Money Matters TV.
By Money Matters TV5
11 ratings
Kimon Hatza, Esq. of GrowthCounsel interviews Nikej N. Shah, M.D., CEO of Nirsum Laboratories about issues in Long-term opioid therapy: Unmet needs, Risks and Solutions with a new drug in Phase I testing with the FDA. Present drugs in use today are Bupremorphine, Methadone and Maltrexone.
The post Money Matters TV 24-42 Shah appeared first on Money Matters TV.